Publications
Detailed Information
Docetaxel+5-fluorouracil plus cisplatin 3-day combination chemotherapy as a first-line treatment in patient with unresectable gastric cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Oh, Do-Youn | - |
dc.contributor.author | Kim, Tae-Yong | - |
dc.contributor.author | Kwon, Jung Hye | - |
dc.contributor.author | Lee, Jae-Jin | - |
dc.contributor.author | Joh, Yohan | - |
dc.contributor.author | Kim, Dong-Wan | - |
dc.contributor.author | Kim, Tae-You | - |
dc.contributor.author | Heo, Dae Seog | - |
dc.contributor.author | Bang, Yung-Jue | - |
dc.contributor.author | Kim, Noe Kyeong | - |
dc.date.accessioned | 2009-12-30T02:00:33Z | - |
dc.date.available | 2009-12-30T02:00:33Z | - |
dc.date.created | 2020-04-08 | - |
dc.date.issued | 2005-07 | - |
dc.identifier.citation | Japanese Journal of Clinical Oncology, Vol.35 No.7, pp.380-385 | - |
dc.identifier.issn | 0368-2811 | - |
dc.identifier.other | 95319 | - |
dc.identifier.uri | https://hdl.handle.net/10371/23421 | - |
dc.description.abstract | Background: Our objective was to verify the efficacy and safety of 'docetaxel + 5-fluorouracil + cisplatin' 3-day combination chemotherapy as a first-line treatment in patients with unresectable gastric cancer. Methods: Between January and November 2002, we enrolled 43 patients [males 31; median age 55 years (range 24-74)] with inoperable gastric cancer who had not been seen previously in Seoul National University Hospital. The regimen used was docetaxel 70 mg/m(2) on day 1, cisplatin 40 mg/m(2) on days 2 and 3, and 5-fluorouracil 1200 mg/m(2) over 10 h on days 1-3, every 3 weeks. Results: A total of 168 cycles were administered. Mean cycle number per patient was 3.9. The administered dose intensity of docetaxel was 21.23 mg/m(2)/week, 5-FU 1092.14 mg/m(2)/week and cisplatin 23.82 mg/m(2)/week, which corresponded to 91.1, 91.0 and 89.5% of planned doses. Of the 43 patients, response evaluation was possible in 40 and, of these patients, 17 (42.5%) achieved a partial response, 13 (32.5%) stable disease, and 10 patients (25%) showed progressive disease. The median time to progression was 5.6 months [95% confidence interval (CI) 4.6-6.6 months]. Median overall survival was 9.0 months. (95% Cl 4.8-13.2 months). Leukopenia occurred during 21.4% of cycles (36 of 168 cycles); 14.3% grade 1, 5.3% grade 2 and 1.8% grade 3. Anemia occurred in 16.7% (28 of 168 cycles); 11.3% grade 1, 4.8% grade 2 and 0.6% grade 3. Thrombocytopenia was not observed. Diarrhea, stomatitis and hypersensitivity occurred in 4.7% (two out of 43 patients), respectively. Neutropenic fever occurred in two patients (4.7%) and myalgia in three (7.0%). Conclusion: 'Docetaxel + 5-fluorouracil + cisplatin' 3-day combination chemotherapy is an active and tolerable regimen as a first-line treatment in patients with unresectable gastric cancer. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | Oxford University Press | - |
dc.title | Docetaxel+5-fluorouracil plus cisplatin 3-day combination chemotherapy as a first-line treatment in patient with unresectable gastric cancer | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 방영주 | - |
dc.identifier.doi | 10.1093/jjco/hyi107 | - |
dc.citation.journaltitle | Japanese Journal of Clinical Oncology | - |
dc.identifier.wosid | 000231348600003 | - |
dc.identifier.scopusid | 2-s2.0-24944592562 | - |
dc.citation.endpage | 385 | - |
dc.citation.number | 7 | - |
dc.citation.startpage | 380 | - |
dc.citation.volume | 35 | - |
dc.identifier.sci | 000231348600003 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Oh, Do-Youn | - |
dc.contributor.affiliatedAuthor | Kim, Dong-Wan | - |
dc.contributor.affiliatedAuthor | Kim, Tae-You | - |
dc.contributor.affiliatedAuthor | Heo, Dae Seog | - |
dc.contributor.affiliatedAuthor | Bang, Yung-Jue | - |
dc.contributor.affiliatedAuthor | Kim, Noe Kyeong | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | PHASE-II TRIAL | - |
dc.subject.keywordPlus | SQUAMOUS-CELL CARCINOMA | - |
dc.subject.keywordPlus | LOCALLY ADVANCED HEAD | - |
dc.subject.keywordPlus | INDUCTION CHEMOTHERAPY | - |
dc.subject.keywordPlus | SUPPORTIVE CARE | - |
dc.subject.keywordPlus | NECK-CANCER | - |
dc.subject.keywordPlus | DOCETAXEL | - |
dc.subject.keywordPlus | FLUOROURACIL | - |
dc.subject.keywordPlus | LEUCOVORIN | - |
dc.subject.keywordPlus | 5-FLUOROURACIL | - |
dc.subject.keywordAuthor | cisplatin | - |
dc.subject.keywordAuthor | docetaxel | - |
dc.subject.keywordAuthor | 5-fluorouracil | - |
dc.subject.keywordAuthor | gastric cancer | - |
dc.subject.keywordAuthor | chemotherapy | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.